Hepatocellular carcinoma (HCC) is the most common type of liver cancer and ranks among the leading causes of cancer-related deaths globally. Traditional treatment methods, including surgical resection ...

Carisma Therapeutics (CARM) announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor ...

In the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the ...

前言一年一度的肿瘤领域盛会——2024年欧洲肿瘤内科学会亚洲年会（ESMO ...

2.1 上海诊疗肝癌流行病学趋势变化（2016—2021年） 2016—2021年，上海市级医院共收治肝癌病人98 960例，其中首次手术病人42 ...

Hepatocellular carcinoma (HCC) is one of the most fatal malignancies. Epigenetic mechanisms have revealed that noncoding RNAs, such as microRNAs (miRNAs) and circular RNAs (circRNAs), are involved ...

Hepatocellular carcinoma (HCC) is one of the most fatal malignancies. Epigenetic mechanisms have revealed that noncoding RNAs ...

A new immune cell biomarker has been discovered that can predict the effectiveness of immune anticancer treatment in patients ...

A newly described stage of a lymph node-like structure seen in liver tumors after presurgical immunotherapy may be vital to ...